Table 1. Baseline Subject Characteristics.
| Placebo (N = 57) | Vitamin D (N = 57) | P-value between treatment groups | |
| Age (years) | 63.6 (3.1) | 64.1 (3.0) | 0.419 |
| Years since menopause | 13.4 (5.1) | 14.1 (6.5) | 0.921 |
| Height (cm) | 164.7 (5.1) | 162.7 (6.8) | 0.083 |
| Weight (lbs) | 151.0 (27.8) | 157.7 (27.4) | 0.114 |
| Body-mass index (kg/m2) | 25.3 (5.1) | 27.1 (4.7) | 0.022 |
| Total 25OH vitamin D (ng/mL) | 32.3 (10.5) | 30.3 (10.7) | 0.353 |
| Calcium (mg/dL) | 9.4 (0.3) | 9.4 (0.4) | 0.862 |
| Glucose (mg/dL) | 97.4 (27.0) | 97.5 (33.5) | 0.978 |
| Total cholesterol (mg/dL) | 202.9 (36.2) | 205.3 (31.0) | 0.650 |
| Triglycerides (mg/dL) | 95.8 (47.4) | 102.0 (50.2) | 0.496 |
| HDL cholesterol (mg/dL) | 70.9 (20.3) | 68.5 (18.5) | 0.516 |
| LDL cholesterol (mg/dL) | 112.9 (32.9) | 116.5 (28.0) | 0.462 |
| Total/HDL cholesterol ratio | 3.1 (0.9) | 3.2 (0.8) | 0.563 |
| C-reactive protein (mg/L) | 1.9 (2.9) | 2.5 (2.9) | 0.287 |
| Brachial artery diameter (cm) | 0.36 (0.04) | 0.36 (0.05) | 0.664 |
| Absolute FMD (cm) | 0.016 (0.018) | 0.018 (0.011) | 0.521 |
| Maximum Relative FMD (%) | 4.57 (3.30) | 5.05 (3.38) | 0.452 |
| Heart rate (bpm) | 59.7 (9.6) | 56.9 (7.0) | 0.157 |
| Brachial SBP (mmHg) | 122.2 (11.8) | 122.3 (13.1) | 0.976 |
| Brachial DBP (mmHg) | 72.6 (7.1) | 72.45 (7.6) | 0.915 |
| * Central SBP (mmHg) | 115.6 (11.1) | 116.7 (12.2) | 0.660 |
| * Central DBP (mmHg) | 73.7 (7.1) | 73.5 (7.7) | 0.893 |
| * Central pulse pressure (mmHg) | 42.1(10.3) | 43.3 (10.4) | 0.581 |
| * Pulse wave velocity (m/s) | 8.0 (1.4) | 7.8 (0.9) | 0.426 |
| * Augmentation index (%) | 27.0 (7.2) | 26.4 (6.5) | 0.695 |
All values are means (standard deviations).
*
Central blood pressures and stiffness measurements were obtained from 37 subjects in the placebo and 38 subjects in the vitamin D arms, respectively.
25OH Vitamin D = 25-hydroxyvitamin D.
DBP = diastolic blood pressure.
FMD = flow-mediated dilation.
HDL = high density lipoprotein.
LDL = low density lipoprotein.
SBP = systolic blood pressure.